{"id":"2946627525-90","name":"SANOFI GENZYME","registrationDate":"2008-10-17T14:57:50.775+01:00","category":2,"subCategory":3,"legal":"Corporation","web":"https://www.sanofigenzyme.com/","country":"United states","headAddress":"Kendall Street, 500","headCity":"Cambridge","headPostCode":"MA 02142","headPhone":"(1)61 72 52 75 00","boss":"David Meeker","bossTitle":"Mr","bossPosition":"Executive Vice President and Head of Sanofi Genzyme","membersCount":3,"membersFTE":"1.0","membership":"Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) &amp; EuropaBio (EU)","memberOrga":"","goal":"Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.","acronym":"Genzyme","interests":"Economic and Financial Affairs, Enterprise, Internal Market, Public Health, Research and Technology","euInitiatives":"rare disease policies, pharmaceutical dossiers and use of biotechnology in health care&#xd;<br />&#xd;<br />in particular in the context of and related to: &#xd;<br />- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products &#xd;<br />&#xd;<br />- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges -  Brussels, 11.11.2008 COM(2008) 679 final&#xd;<br />- EU Net HTA Joint action&#xd;<br />- RD Action Joint Action&#xd;<br />- IMI","lastUp":"2017-03-02T17:24:13.534+01:00","customers":"","costAbsolu":"","costRange":"400000-499999","turnoverAbsolu":0,"turnoverRange":""}